Hallock G G
Division of Plastic Surgery at Allentown Affiliated Hospitals, PA.
Plast Reconstr Surg. 1987 Oct;80(4):567-9. doi: 10.1097/00006534-198710000-00015.
An ex vivo study was undertaken to document the maximum possible overinflation of tissue expanders with a comparison of all major manufacturers. Ten standard round implants from each vendor were expanded. Mean overinflation varied from 33 to 99 times stated capacity, with a range from 16 to 157 times this volume. The mechanism of failure in 93 percent of implants was envelope rupture. Overexpansion appears safe without risk of implant failure at least to 15 times vendors' stated maximum volume.
进行了一项体外研究，以记录所有主要制造商的组织扩张器的最大可能过度膨胀情况，并进行比较。对每个供应商的十个标准圆形植入物进行了扩张。平均过度膨胀倍数从规定容量的33倍到99倍不等，范围为该体积的16倍到157倍。93%的植入物的失效机制是包膜破裂。至少在达到供应商规定的最大体积的15倍时，过度扩张似乎是安全的，不会有植入物失效的风险。
